Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Custom 3D Printable Silicones with Tunable Stiffness.

Durban MM, Lenhardt JM, Wu AS, Small W 4th, Bryson TM, Perez-Perez L, Nguyen DT, Gammon S, Smay JE, Duoss EB, Lewicki JP, Wilson TS.

Macromol Rapid Commun. 2018 Feb;39(4). doi: 10.1002/marc.201700563. Epub 2017 Dec 6.

PMID:
29210493
2.

WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death.

Fischer MM, Cancilla B, Yeung VP, Cattaruzza F, Chartier C, Murriel CL, Cain J, Tam R, Cheng CY, Evans JW, O'Young G, Song X, Lewicki J, Kapoun AM, Gurney A, Yen WC, Hoey T.

Sci Adv. 2017 Jun 21;3(6):e1700090. doi: 10.1126/sciadv.1700090. eCollection 2017 Jun.

3.

3D-Printing of Meso-structurally Ordered Carbon Fiber/Polymer Composites with Unprecedented Orthotropic Physical Properties.

Lewicki JP, Rodriguez JN, Zhu C, Worsley MA, Wu AS, Kanarska Y, Horn JD, Duoss EB, Ortega JM, Elmer W, Hensleigh R, Fellini RA, King MJ.

Sci Rep. 2017 Mar 6;7:43401. doi: 10.1038/srep43401.

4.

Shape-morphing composites with designed micro-architectures.

Rodriguez JN, Zhu C, Duoss EB, Wilson TS, Spadaccini CM, Lewicki JP.

Sci Rep. 2016 Jun 15;6:27933. doi: 10.1038/srep27933.

5.

Corrigendum: 3D printed cellular solid outperforms traditional stochastic foam in long-term mechanical response.

Maiti A, Small W, Lewicki JP, Weisgraber TH, Duoss EB, Chinn SC, Pearson MA, Spadaccini CM, Maxwell RS, Wilson TS.

Sci Rep. 2016 May 25;6:26573. doi: 10.1038/srep26573. No abstract available.

6.

3D printed cellular solid outperforms traditional stochastic foam in long-term mechanical response.

Maiti A, Small W, Lewicki JP, Weisgraber TH, Duoss EB, Chinn SC, Pearson MA, Spadaccini CM, Maxwell RS, Wilson TS.

Sci Rep. 2016 Apr 27;6:24871. doi: 10.1038/srep24871. Erratum in: Sci Rep. 2016 May 25;6:26573.

7.

Soft Materials with Recoverable Shape Factors from Extreme Distortion States.

Goff J, Sulaiman S, Arkles B, Lewicki JP.

Adv Mater. 2016 Mar 23;28(12):2393-8. doi: 10.1002/adma.201503320. Epub 2016 Jan 20.

8.

Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.

Chartier C, Raval J, Axelrod F, Bond C, Cain J, Dee-Hoskins C, Ma S, Fischer MM, Shah J, Wei J, Ji M, Lam A, Stroud M, Yen WC, Yeung P, Cancilla B, O'Young G, Wang M, Kapoun AM, Lewicki J, Hoey T, Gurney A.

Cancer Res. 2016 Feb 1;76(3):713-23. doi: 10.1158/0008-5472.CAN-15-0561. Epub 2015 Dec 30.

9.

Correction: Nanoscale structure and superhydrophobicity of sp(2)-bonded boron nitride aerogels.

Pham T, Goldstein AP, Lewicki JP, Kucheyev SO, Wang C, Russell TP, Worsley MA, Woo L, Mickelson W, Zettl A.

Nanoscale. 2016 Jan 21;8(3):1705. doi: 10.1039/c5nr90227d.

PMID:
26676371
10.

Nanoscale structure and superhydrophobicity of sp(2)-bonded boron nitride aerogels.

Pham T, Goldstein AP, Lewicki JP, Kucheyev SO, Wang C, Russell TP, Worsley MA, Woo L, Mickelson W, Zettl A.

Nanoscale. 2015 Jun 21;7(23):10449-58. doi: 10.1039/c5nr01672j. Erratum in: Nanoscale. 2016 Jan 21;8(3):1705.

PMID:
26007693
11.

Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.

Yen WC, Fischer MM, Axelrod F, Bond C, Cain J, Cancilla B, Henner WR, Meisner R, Sato A, Shah J, Tang T, Wallace B, Wang M, Zhang C, Kapoun AM, Lewicki J, Gurney A, Hoey T.

Clin Cancer Res. 2015 May 1;21(9):2084-95. doi: 10.1158/1078-0432.CCR-14-2808.

12.

Encapsulated liquid sorbents for carbon dioxide capture.

Vericella JJ, Baker SE, Stolaroff JK, Duoss EB, Hardin JO 4th, Lewicki J, Glogowski E, Floyd WC, Valdez CA, Smith WL, Satcher JH Jr, Bourcier WL, Spadaccini CM, Lewis JA, Aines RD.

Nat Commun. 2015 Feb 5;6:6124. doi: 10.1038/ncomms7124.

PMID:
25652243
13.

Oxygen-dependent acetylation and dimerization of the corepressor CtBP2 in neural stem cells.

Karaca E, Lewicki J, Hermanson O.

Exp Cell Res. 2015 Mar 1;332(1):128-35. doi: 10.1016/j.yexcr.2014.10.013. Epub 2014 Oct 30.

14.

Advances in modeling sorption and diffusion of moisture in porous reactive materials.

Harley SJ, Glascoe EA, Lewicki JP, Maxwell RS.

Chemphyschem. 2014 Jun 23;15(9):1809-20. doi: 10.1002/cphc.201301097. Epub 2014 May 12.

PMID:
24819028
15.

Electron Beam Crosslinked Polyurethane Shape Memory Polymers with Tunable Mechanical Properties.

Hearon K, Nash LD, Volk BL, Ware T, Lewicki JP, Voit WE, Wilson TS, Maitland DJ.

Macromol Chem Phys. 2013 Jun 1;214(11):1258-1272.

16.

Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells.

Yen WC, Fischer MM, Hynes M, Wu J, Kim E, Beviglia L, Yeung VP, Song X, Kapoun AM, Lewicki J, Gurney A, Simeone DM, Hoey T.

Clin Cancer Res. 2012 Oct 1;18(19):5374-86. doi: 10.1158/1078-0432.CCR-12-0736. Epub 2012 Sep 5.

17.

Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors.

Petrillo LA, Wolf DM, Kapoun AM, Wang NJ, Barczak A, Xiao Y, Korkaya H, Baehner F, Lewicki J, Wicha M, Park JW, Spellman PT, Gray JW, Van't Veer L, Esserman LJ.

Breast Cancer Res Treat. 2012 Oct;135(3):913-22. doi: 10.1007/s10549-012-2226-y. Epub 2012 Sep 2.

18.

Mechanically robust 3D graphene macroassembly with high surface area.

Worsley MA, Kucheyev SO, Mason HE, Merrill MD, Mayer BP, Lewicki J, Valdez CA, Suss ME, Stadermann M, Pauzauskie PJ, Satcher JH Jr, Biener J, Baumann TF.

Chem Commun (Camb). 2012 Aug 28;48(67):8428-30. doi: 10.1039/c2cc33979j. Epub 2012 Jul 13.

PMID:
22797515
19.

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors.

Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L, Fischer M, Chaudhari A, Ji M, Kapoun AM, Lam A, Lazetic S, Ma S, Mitra S, Park IK, Pickell K, Sato A, Satyal S, Stroud M, Tran H, Yen WC, Lewicki J, Hoey T.

Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11717-22. doi: 10.1073/pnas.1120068109. Epub 2012 Jul 2.

20.

Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.

Fischer M, Yen WC, Kapoun AM, Wang M, O'Young G, Lewicki J, Gurney A, Hoey T.

Cancer Res. 2011 Mar 1;71(5):1520-5. doi: 10.1158/0008-5472.CAN-10-2817. Epub 2010 Dec 30.

21.

DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.

Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, Fitch-Bruhns M, Lazetic S, Park IK, Sato A, Satyal S, Wang X, Clarke MF, Lewicki J, Gurney A.

Cell Stem Cell. 2009 Aug 7;5(2):168-77. doi: 10.1016/j.stem.2009.05.019.

22.

The stability of polysiloxanes incorporating nano-scale physical property modifiers.

Lewicki JP, Patel M, Morrell P, Liggat J, Murphy J, Pethrick R.

Sci Technol Adv Mater. 2008 Jul 7;9(2):024403. eCollection 2008 Apr.

23.

Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy.

Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L, Pickell K, Aguilar J, Lazetic S, Smith-Berdan S, Clarke MF, Hoey T, Lewicki J, Gurney AL.

PLoS One. 2008 Jun 18;3(6):e2428. doi: 10.1371/journal.pone.0002428. Erratum in: PLoS ONE. 2008;3(8). doi: 10.1371/annotation/2aa6a20a-e63c-49b6-aeea-aae62435617f.

24.

Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors.

Cho RW, Wang X, Diehn M, Shedden K, Chen GY, Sherlock G, Gurney A, Lewicki J, Clarke MF.

Stem Cells. 2008 Feb;26(2):364-71. Epub 2007 Nov 1.

25.

The prognostic role of a gene signature from tumorigenic breast-cancer cells.

Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF.

N Engl J Med. 2007 Jan 18;356(3):217-26.

26.

Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4.

Chang TL, Chang CH, Simpson DA, Xu Q, Martin PK, Lagenaur LA, Schoolnik GK, Ho DD, Hillier SL, Holodniy M, Lewicki JA, Lee PP.

Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11672-7. Epub 2003 Sep 12.

27.

Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue.

Mavunkel BJ, Chakravarty S, Perumattam JJ, Luedtke GR, Liang X, Lim D, Xu YJ, Laney M, Liu DY, Schreiner GF, Lewicki JA, Dugar S.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):3087-90.

PMID:
12941340
28.

The fate of nitrogen from 15N-labeled nitrate after single intravenous administration of Na15NO3 in sheep.

Lewicki J, Wiechetek M, Souffrant WB, Karlik W, Garwacki S.

Can J Physiol Pharmacol. 1998 Sep;76(9):850-7.

PMID:
10066134
29.

Lipid levels and peripheral vascular disease in diabetic and non-diabetic subjects.

O'Neal DN, Lewicki J, Ansari MZ, Matthews PG, Best JD.

Atherosclerosis. 1998 Jan;136(1):1-8.

PMID:
9544725
30.

Marketing authorization of veterinary medicinal products in Poland.

Sztabińska-Koncka H, Lewicki J.

Regul Toxicol Pharmacol. 1997 Aug;26(1 Pt 1):129-33.

PMID:
9339489
31.

A study of the pharmacokinetics and tissue residues of an oral trimethoprim/sulphadiazine formulation in healthy pigs.

Garwacki S, Lewicki J, Wiechetek M, Grys S, Rutkowski J, Zaremba M.

J Vet Pharmacol Ther. 1996 Dec;19(6):423-30.

PMID:
8971670
32.

Computer-assisted antimicrobial surveillance in a community teaching hospital.

Jozefiak ET, Lewicki JE, Kozinn WP.

Am J Health Syst Pharm. 1995 Jul 15;52(14):1536-40.

PMID:
7552895
33.

Role of natriuretic peptide clearance receptor in in vivo control of C-type natriuretic peptide.

Brandt RR, Heublein DM, Aarhus LL, Lewicki JA, Burnett JC Jr.

Am J Physiol. 1995 Jul;269(1 Pt 2):H326-31.

PMID:
7631865
34.

Oral bioavailability and pharmacokinetics of baquiloprim in dwarf goats.

Lewicki J, Maas RF, Witkamp RF, Van-Miert AS.

Res Vet Sci. 1995 May;58(3):268-71.

PMID:
7659854
35.

Clearance receptor-mediated control of atrial natriuretic factor in experimental congestive heart failure.

Brandt RR, Redfield MM, Aarhus LL, Lewicki JA, Burnett JC Jr.

Am J Physiol. 1994 Mar;266(3 Pt 2):R936-43.

PMID:
8160889
36.

Biologic role of atrial natriuretic factor clearance receptor in congestive heart failure.

Perrella MA, Aarhus LL, Heublein DM, Lewicki JA, Burnett JC Jr.

Am J Physiol. 1993 Jul;265(1 Pt 2):H401-8.

PMID:
8342659
37.

Effect of nitrite on ureagenesis and carbohydrate metabolism in isolated rat hepatocytes.

Wiechetek M, Garwacki S, Karlik W, Lewicki J, Souffrant W.

Arch Environ Contam Toxicol. 1993 Apr;24(3):375-80.

PMID:
8470937
38.

C-type natriuretic peptide inhibits growth factor-dependent DNA synthesis in smooth muscle cells.

Porter JG, Catalano R, McEnroe G, Lewicki JA, Protter AA.

Am J Physiol. 1992 Nov;263(5 Pt 1):C1001-6.

PMID:
1359791
39.

Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor.

Okolicany J, McEnroe GA, Koh GY, Lewicki JA, Maack T.

Am J Physiol. 1992 Sep;263(3 Pt 2):F546-53.

PMID:
1415584
40.

ANP-(7-23) stimulates a DHP-sensitive Ca2+ conductance and reduces cellular cAMP via a cGMP-independent mechanism.

Isales CM, Lewicki JA, Nee JJ, Barrett PQ.

Am J Physiol. 1992 Aug;263(2 Pt 1):C334-42.

PMID:
1325113
41.

Effects of small C-ANF receptor ligands on plasma levels of atrial natriuretic factor, blood pressure, and renal function in the rat.

Okolicany J, McEnroe GA, Gregory LC, Lewicki JA, Maack T.

Can J Physiol Pharmacol. 1991 Oct;69(10):1561-6.

PMID:
1663817
42.

Cellular mechanisms of the clearance function of type C receptors of atrial natriuretic factor.

Nussenzveig DR, Lewicki JA, Maack T.

J Biol Chem. 1990 Dec 5;265(34):20952-8.

43.

Hemodynamic effects of atrial natriuretic factor clearance receptor occupancy in conscious sheep.

Parkes DG, Coghlan JP, Lewicki JA, Scarborough RM, Scoggins BA.

Am J Hypertens. 1990 Nov;3(11):829-32.

PMID:
2175624
44.

Isolation and functional expression of the human atrial natriuretic peptide clearance receptor cDNA.

Porter JG, Arfsten A, Fuller F, Miller JA, Gregory LC, Lewicki JA.

Biochem Biophys Res Commun. 1990 Sep 14;171(2):796-803.

PMID:
2169733
45.

Human and canine gene homologs of porcine brain natriuretic peptide.

Seilhamer JJ, Arfsten A, Miller JA, Lundquist P, Scarborough RM, Lewicki JA, Porter JG.

Biochem Biophys Res Commun. 1989 Dec 15;165(2):650-8.

PMID:
2597152
46.

Expression and regulation of ANP receptor subtypes in rat renal glomeruli and papillae.

Martin ER, Lewicki JA, Scarborough RM, Ballermann BJ.

Am J Physiol. 1989 Oct;257(4 Pt 2):F649-57.

PMID:
2552835
47.

Recombinant expression of a secreted form of the atrial natriuretic peptide clearance receptor.

Porter JG, Scarborough RM, Wang Y, Schenk D, McEnroe GA, Kang LL, Lewicki JA.

J Biol Chem. 1989 Aug 25;264(24):14179-84.

48.

Cloning of a cDNA encoding porcine brain natriuretic peptide.

Porter JG, Arfsten A, Palisi T, Scarborough RM, Lewicki JA, Seilhamer JJ.

J Biol Chem. 1989 Apr 25;264(12):6689-92.

49.

Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution.

Sielecki AR, Hayakawa K, Fujinaga M, Murphy ME, Fraser M, Muir AK, Carilli CT, Lewicki JA, Baxter JD, James MN.

Science. 1989 Mar 10;243(4896):1346-51.

PMID:
2493678
50.

Clearance function of type C receptors of atrial natriuretic factor in rats.

Almeida FA, Suzuki M, Scarborough RM, Lewicki JA, Maack T.

Am J Physiol. 1989 Feb;256(2 Pt 2):R469-75.

PMID:
2537040

Supplemental Content

Loading ...
Support Center